Target family: Bradykinin receptors (type: gpcr)
Target: B<sub>1</sub> receptor

Ligand: Ac-Lys-[MeAla6,Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.2 pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: B-10356 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Median affinity:  pKi
Reference (Journal): Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism.
Published in: J Pharmacol Exp Ther

Ligand: B-9430 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.9 pKi
Reference (Journal): A new generation of bradykinin antagonists.
Published in: Immunopharmacology

Ligand: B-9430 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.099999904632568 pA2
Reference (Journal): Bradykinin receptors and their antagonists.
Published in: Eur J Pharmacol

Ligand: B-9430 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pA2
Reference (Journal): Bradykinin receptors and their antagonists.
Published in: Eur J Pharmacol

Ligand: B-9430 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.6 pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: B-9430 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.9 pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: B-9858 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.3 pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: B-9858 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: B-9858 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pA2
Reference (Journal): Bradykinin receptors and their antagonists.
Published in: Eur J Pharmacol

Ligand: B-9858 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: B-9858 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists.
Published in: J Biol Chem

Ligand: B-9858 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: B-9958 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism.
Published in: J Pharmacol Exp Ther

Ligand: B-9958 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Bradykinin receptors and their antagonists.
Published in: Eur J Pharmacol

Ligand: bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 4 pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.7 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: chroman 28 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.
Published in: J Med Chem

Ligand: chroman 28 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.5 pIC50
Reference (Journal): Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.
Published in: J Med Chem

Ligand: compound 11 [PMID: 12812482] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.2 pKi
Reference (Journal): Discovery of a potent, non-peptide bradykinin B1 receptor antagonist.
Published in: J Am Chem Soc

Ligand: compound 11 [PMID: 12812482] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 10.5 pKi
Reference (Journal): Discovery of a potent, non-peptide bradykinin B1 receptor antagonist.
Published in: J Am Chem Soc

Ligand: compound 12 [PMID: 12723943] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): Benzodiazepines as potent and selective bradykinin B1 antagonists.
Published in: J Med Chem

Ligand: compound 12 [PMID: 12723943] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9.2 pKi
Reference (Journal): Benzodiazepines as potent and selective bradykinin B1 antagonists.
Published in: J Med Chem

Ligand: [des-Arg10]icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.6 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: [des-Arg10]icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pA2
Reference (Journal): Bradykinin receptors and their antagonists.
Published in: Eur J Pharmacol

Ligand: [des-Arg10]icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg10]icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg10]icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: [des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: [des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: [des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: [des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Receptors for kinins in the human isolated umbilical vein.
Published in: Br J Pharmacol

Ligand: [des-Arg11]T-kinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg11]T-kinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: [des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: [des-Phe9,des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: [des-Pro8,des-Phe9,des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: EMA (2008), FDA (2011)
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: EMA (2008), FDA (2011)
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: icatibant (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: EMA (2008), FDA (2011)
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: JMV1431 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.1 pKi
Reference (Journal): Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.
Published in: J Med Chem

Ligand: kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.3 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.3 pKi
Reference (Journal): Differential pharmacology of cloned human and mouse B2 bradykinin receptors.
Published in: Mol Pharmacol

Ligand: kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Median affinity: 7.3 pEC50
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pA2
Reference (Journal): Kinin B1 and B2 receptors in the mouse.
Published in: Can J Physiol Pharmacol

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.4 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression cloning of a human B1 bradykinin receptor.
Published in: J Biol Chem

Ligand: [Leu8,des-Arg9]bradykinin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657.
Published in: Mol Pharmacol

Ligand: [Leu9,des-Arg10]kallidin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.9 pIC50
Reference (Journal): Expression cloning of a human B1 bradykinin receptor.
Published in: J Biol Chem

Ligand: [Leu9,des-Arg10]kallidin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors.
Published in: Immunopharmacology

Ligand: [Leu9,des-Arg10]kallidin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: [Leu9,des-Arg10]kallidin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization.
Published in: Br J Pharmacol

Ligand: [Leu9,des-Arg10]kallidin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pA2
Reference (Journal): Kinin B1 and B2 receptors in the mouse.
Published in: Can J Physiol Pharmacol

Ligand: Lys-kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: Met-Lys-bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.1 pIC50
Reference (Journal): Expression cloning of a human B1 bradykinin receptor.
Published in: J Biol Chem

Ligand: NG29 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pIC50
Reference (Journal): Safety and pharmacokinetics of a kinin B1 receptor peptide agonist produced with different counter-ions.
Published in: Biol Chem

Ligand: NPC 17731 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.9 pKi
Reference (Journal): The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists.
Published in: J Biol Chem

Ligand: NPC 18565 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 10.2 pKi
Reference (Journal): The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists.
Published in: J Biol Chem

Ligand: NVP-SAA164 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor.
Published in: Br J Pharmacol

Ligand: NVP-SAA164 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.
Published in: J Med Chem

Ligand: PS020990 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.2 pKi
Reference (Journal): Small molecule antagonists of the bradykinin B1 receptor.
Published in: Immunopharmacology

Ligand: R-715 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: R-715 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.4 pKi
Reference (Journal): Partial agonists and full antagonists at the human and murine bradykinin B1 receptors.
Published in: Can J Physiol Pharmacol

Ligand: R-715 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7 pA2
Reference (Journal): Kinin B1 and B2 receptors in the mouse.
Published in: Can J Physiol Pharmacol

Ligand: R-715 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pA2
Reference (Journal): Structure-activity studies of B1 receptor-related peptides. Antagonists.
Published in: Hypertension

Ligand: R-954 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pA2
Reference (Journal): Preclinical pharmacology, metabolic stability, pharmacokinetics and toxicology of the peptidic kinin B1 receptor antagonist R-954.
Published in: Peptides

Ligand: [Sar,D-Phe8,des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [Sar,D-Phe8,des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: [Sar,D-Phe8,des-Arg9]bradykinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pKi
Reference (Journal): Cardiovascular effects of Sar-[D-Phe8]des-Arg9-bradykinin, a metabolically protected agonist of B1 receptor for kinins, in the anesthetized rabbit pretreated with a sublethal dose of bacterial lipopolysaccharide.
Published in: J Pharmacol Exp Ther

Ligand: D-Lys0-[des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.5 pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: [D-Lys1,des-Arg10]kallidin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways.
Published in: J Biol Chem

Ligand: SSR240612 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.
Published in: J Pharmacol Exp Ther

Ligand: [125I]Hpp-desArg10HOE140 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKd

Ligand: [125I]Hpp-desArg10HOE140 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKd
Reference (Journal): Autoradiographic detection of kinin receptors in the human medulla of control, hypertensive, and diabetic donors.
Published in: Can J Physiol Pharmacol

Ligand: [125I]Hpp-desArg10HOE140 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10 pKd
Reference (Journal): Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier.
Published in: J Neurotrauma

Ligand: [3H]Lys-[des-Arg9]BK (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.4 pKd

Ligand: [3H]Lys-[Leu8][des-Arg9]BK (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -

Ligand: T-kinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.2 pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol

Ligand: T-kinin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Molecular characterisation of cloned bradykinin B1 receptors from rat and human.
Published in: Eur J Pharmacol